CCM
ZSAN

CAAS Capital Management’s Zosano Pharma Corporation ZSAN Stock Holding History

CAAS Capital Management’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,948
Closed -$734K – 965
2020
Q3 		$734K Buy
+12,948
New +$603K 0.02% 365

Other funds holding ZSAN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAAS Capital Management's ZSAN Position: Q4 2020 in Review

CAAS Capital Management sold out of Zosano Pharma Corporation (ZSAN) in Q4 2020, closing a stake of 12,948 shares — an estimated $734K sold.

CAAS Capital Management first reported a position in ZSAN in Q3 2020 and held it in 1 quarter. The position peaked at $734K in Q3 2020. 34 funds tracked by Wall St. Rank hold ZSAN as of Q4 2020.

  • CAAS Capital Management reported no remaining Zosano Pharma Corporation position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 12,948 Zosano Pharma Corporation shares in Q4 2020, an estimated $734K.
  • CAAS Capital Management first reported a position in Zosano Pharma Corporation in Q3 2020 and held it in 1 quarter.
  • CAAS Capital Management's Zosano Pharma Corporation position peaked at $734K in Q3 2020.
  • 34 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.